Connect your AI

Schrodinger SDGR Drug discovery — Deferred revenue, revenue recognized

Other product segments

Software products and services

$24.8M-15.9%

Similar metrics at other companies

DJT

DJTDeferred Revenue Revenue Recognized1

$30.4K—

ARWRDeferred Revenue

$108.54M+151%

ARDeferred Revenue Revenue Recognized1

$5.8M-7.0%

PAYCRevenue recognized that was included in deferred income at the beginning of the period

$9M-5.3%

IONSDeferred Revenue

$69.2M-14.7%

TNLDeferred Revenue

$478M-1.6%

Other financials

Income statement

Revenue$58.6M-1.6%

Gross profit$29.5M-5.1%

Operating income-$48.8M+4.1%

Net income-$60.0M-0.4%

EPS (diluted)-$0.81+1.2%

Balance sheet

Cash & equivalents$267.7M-20.7%

Total debt$107.0M-7.9%

Total equity$313.5M-16.1%

Total assets$634.2M-14.6%

Cash flow

Operating cash flow-$14.8M-110%

CapEx$2.5M+321%

Free cash flow-$17.3M-112%

Valuation

Market cap$1.15B-23.7%

Enterprise value$984.71M-23.1%

P/S4.5×-2.0×

Profitability

Gross margin55.3%-7.3pp

Operating margin-64.7%-12.0pp

Net margin-68.5%—

FCF margin9.6%+5.1pp

Returns & leverage

Return on equity-45.7%—

Debt / equity0.3×0.0×

Current ratio2.7×-0.7×

Where this comes from

Reported directly by Schrodinger in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityRevenueRecognized.

The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schrodinger's drug discovery — deferred revenue, revenue recognized.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Schrodinger's drug discovery — deferred revenue, revenue recognized?: Schrodinger (SDGR) reported drug discovery — deferred revenue, revenue recognized of $22.4M in Q1 2026.
What does drug discovery — deferred revenue, revenue recognized mean?: This represents the amount of previously deferred revenue that has been recognized in the current period as performance obligations are satisfied. It demonstrates the conversion of contract liabilities into actual realized revenue.